Decapeptyl® SR 22.5mg + Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
ApprovedTerminated 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Aug 1, 2012 → Feb 1, 2014
NCT ID
NCT01673984About Decapeptyl® SR 22.5mg + Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
Decapeptyl® SR 22.5mg + Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg is a approved stage product being developed by Ipsen for Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01673984. Target conditions include Prostate Cancer.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01673984 | Approved | Terminated |
Competing Products
20 competing products in Prostate Cancer